Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition
作者:Yufei Han、Ye Tian、Ruxin Wang、Siyu Fu、Jia Jiang、Jiawen Dong、Mingze Qin、Yunlei Hou、Yanfang Zhao
DOI:10.1016/j.bioorg.2020.104197
日期:2020.11
position are optimal fragments. Compound 18b showed the most potent in vitro activity (PI3Kα IC50 = 0.46 nM, mTOR IC50 = 12 nM), as well as good inhibition against PC-3 (human prostate cancer), HCT-116 (human colorectal cancer), A549 (human lung adenocarcinoma) and MDA-MB-231 (human breast cancer) cell lines. Furthermore, Annexin-V and propidium iodide (PI) double staining confirmed that 18b induces apoptosis
最近,PI3K和mTOR被认为是治疗癌症的有希望的靶标。在这里,我们设计和合成了四个系列的新的噻吩并[3,2- d ]嘧啶衍生物,其中含有芳酰基或芳基酰肼部分。这些衍生物充当PI3K / mTOR双重抑制剂,表明它们可用作癌症治疗剂。测试所有化合物对四种癌细胞系的抗增殖活性。通过改变噻吩并[3,2- d ]嘧啶核的C-6和C-2位置的部分进行结构-活性关系(SAR)研究。表明C-6位的芳基酰肼和C-2位的2-氨基嘧啶是最佳片段。化合物18b表现出最强的体外活性(PI3KαIC 50 = 0.46 nM,mTOR IC 50 = 12 nM),并对PC-3(人前列腺癌),HCT-116(人结肠直肠癌),A549(人肺腺癌)和MDA-MB-231(人乳腺癌)细胞系。此外,Annexin-V和碘化丙锭(PI)双重染色证实18b诱导细胞毒性HCT-116细胞凋亡。此外,在HCT-116细胞系上